EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
7.10
-0.02 (-0.28%)
Dec 20, 2024, 4:00 PM EST - Market closed
EyePoint Pharmaceuticals Employees
EyePoint Pharmaceuticals had 121 employees as of December 31, 2023. The number of employees decreased by 23 or -15.97% compared to the previous year.
Employees
121
Change (1Y)
-23
Growth (1Y)
-15.97%
Revenue / Employee
$377,793
Profits / Employee
-$855,950
Market Cap
498.14M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Auna S.A. | 14,958 |
Talkspace | 472 |
MeiraGTx Holdings | 425 |
Sangamo Therapeutics | 405 |
Semler Scientific | 92 |
Terns Pharmaceuticals | 66 |
ABIVAX Société Anonyme | 61 |
Cartesian Therapeutics | 38 |
EYPT News
- 5 days ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration - GlobeNewsWire
- 5 weeks ago - EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
- 6 weeks ago - EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - GlobeNewsWire
- 7 weeks ago - EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 7 weeks ago - EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - GlobeNewsWire